1.Adams, M., McCall, N., & Gray, D.Economic analysis in randomized control trials. Medical Care, 1992, 30, 231–43.
2.Broome, J.QALYs. Journal of Public Economics, 1992, 50, 149–67.
3.Drummond, M.Economic evaluation of Pharmaceuticals: Science or marketing? PharmacoEconomics, 1992, 1, 8–13.
4.Drummond, M., Rutter, F., Brenna, A. et al. Economic evaluation of Pharmaceuticals: A European perspective. PharmacoEconomics, 1993, 4, 173–86.
5.Drummond, M., & Davies, L.Economic analysis alongside clinical trials: Revisiting the methodological issues. International Journal of Technology Assessment in Health Care, 1991, 7, 561–73.
6.Drummond, M. G., Stoddart, G., & Torrance, G. W.Methods for the economic evaluation of health care programs. Oxford: Oxford Medical Publications, 1987.
7.Gramlich, E. M.A guide to benefit-cost analysis. Englewood Cliffs, NJ: Prentice Hall, 1990.
8.Guyatt, G., Drummond, M., Feeny, D. et al. Guidelines for the clinical and economic evaluation of health care technologies. Social Science and Medicine, 1986, 22, 393–408.
9. Henry, D. Economic analysis as an aid to subsidization: The development of Australian guidelines for Pharmaceuticals. PharmacoEconomics, 1992, 54–67.
10.Hillman, A., Eisenberg, J., Pauly, M. et al. Avoiding bias in the conduct of cost effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine, 1991, 324, 1362–65.
11.Hutton, J.Economic evaluation of health care: A half-way technology. Health Economics, 1994, 3, 1–4.
12.Jonsson, B.Cost-benefit analysis of hepatitis B vaccination. Postgraduate Medical Journal, 1987, 63(suppl. 2), 27–32.
13.Katz, D. A., & Welch, G.Discounting in cost-effectiveness analysis of health care programs. PharmacoEconomics, 1993, 3, 276–85.
14.Mooney, G., & Olson, J. A. QALYs: Where next? In Mcguire, A.Fenn, P., & Meyhew, K. (eds.) Providing health care. Oxford: Oxford University Press, 1991, 120–40.
15.Nord, E.Toward quality assurance in QALY calculations. International Journal of Technology Assessment in Health Care, 1993, 9, 37–45.
16.Nord, E., Richardson, J., & Macarounas-Kirchman, K.Social evaluation of health care versus personal evaluation of health states: Evidence on the validity of four health-state scaling instruments using Norwegian and Australian data. International Journal of Technology Assessment in Health Care, 1993, 9, 463–78.
17. OECD. Managing with market-type mechanisms. Paris: Public Management Studies, 1993.
18.Olson, J. A.Persons versus years: Two ways of eliciting implicit weights. Health Economics,1994, 3, 39–46.
19.Petrou, S., Malek, M., & Davey, P. G.The reliability of cost-utility estimates in cost-per-QALY league tables. PharmacoEconomics, 1993, 3, 345–53.
20.Russell, L. B.Is prevention better than cure? Washington, DC: The Brookings Institution, 1986.
21.Scherer, F. M.Pricing, profits and technological progress in the pharmaceutical industry. Journal of Economic Perspectives, 1993, 7, 97–115.
22.Sheldon, T. A.Discounting in health care decision-making: Time for a change? Journal of Public Health Medicine, 1992, 14, 250-56.
23.Smith, R. D., & Dobson, M.Measuring utility values for QALYs: Two methodological issues. Health Economics, 1993, 2, 349–55.
24.Udvarhelyi, S., Colditz, G., Rai, A. et al. Cost-effectiveness and cost-benefit analysis in the medical literature: Are the methods being used correctly? Annals of Internal Medicine, 1992, 116, 238–44.
25.Weinstein, M.Principles of cost-effective resource allocation in health care organizations. International Journal of Technology Assessment in Health Care, 1990, 6, 93–103.
26.Weinstein, M., & Fineberg, H. V.Clinical decision analysis. New York: W. B. Saunders, 1980.
27.Weisbrod, B. A.The health care quadrilemma: An essay on technological change, insurance, quality of care, and cost containment. Journal of Economic Literature, 1991, 24, 523–52.